Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)
A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
pchop123
(76.62)
Submitted: 6/14/2013 3:38:02 PM :
Start Price:
$5.18
IDIX Score:
-2.12
short term upside very unlikely
Recs
zzlangerhans
(99.76)
Submitted: 6/4/2013 10:25:06 PM :
Start Price:
$4.88
IDIX Score:
-8.29
I find it difficult to value hepatitis C stocks but Idenix has risen sharply over the last three weeks without a clear precipitant that I can identify. The company announced plans for a phase II trial of all-oral combination of IDX719 and Janssen's simeprevir in their last earnings call, but this was fairly predictable after the announcement of the Janssen collaboration in January. Hepatitis C may still be an exciting and lucrative field but there's loads of competition and Idenix seems to be years behind in the development of all oral regimens.
Recs
Recs
genedom
(98.24)
Submitted: 4/5/2012 12:02:38 AM :
Start Price:
$8.90
IDIX Score:
+57.83
Over valued.
Recs
phatchips767
(< 20)
Submitted: 3/12/2012 2:47:45 PM :
Start Price:
$11.19
IDIX Score:
-71.57
went up 269% for portofeille.
Recs
generaltso10
(< 20)
Submitted: 3/2/2012 12:47:25 AM :
Start Price:
$12.02
IDIX Score:
-74.74
undervalued bio tech
Recs
sunnyspot
(80.27)
Submitted: 2/5/2012 12:46:17 PM :
Start Price:
$11.39
IDIX Score:
+75.55
Despite strong growth in recent months, Gilead Sciences beat them to the punch on hepatitis C, upon which Idenix had hung its hopes. A rebound may take a while.
Recs
getrichslowfool
(< 20)
Submitted: 1/13/2012 3:20:40 PM :
Start Price:
$14.76
IDIX Score:
-91.14
It is going to get bought out, likely for more than the 2.5 billion or whatever INHX got. I'm thinking 30-35 bucks per share.
Recs
geomedf
(< 20)
Submitted: 1/11/2012 2:03:45 AM :
Start Price:
$12.29
IDIX Score:
-83.93
Wild card is IDIX over ACHN as only remaining Nuc therapy for hep C, as VRUS and INHS both were acquired at huge premium in this narrowed space competing to develop an all-oral hepatitis C therapy for this epidemic worldwide valued at as much as $3 billion. IDIX has broken out but expect it to run up significantly in the near term based on valuation, pipeline, short covers and new valuation of 18.
Recs
portefeuille
(99.75)
Submitted: 12/8/2011 1:55:09 PM :
Start Price:
$3.05
IDIX Score:
+49.35
There are currently 4000 IDIX shares in my "fund" with break-even of around 5.92 USD.
http://caps.fool.com/Blogs/fund-trades/671856.
Recs
Recs
ztaylor40
(79.31)
Submitted: 1/24/2010 9:42:13 PM :
Start Price:
$2.78
IDIX Score:
+41.98
When should I buy this stock? Plz help....
Recs
sigeptrooper02
(43.67)
Submitted: 11/22/2009 2:59:25 PM :
Start Price:
$1.88
IDIX Score:
+133.76
spec
Recs
cashsage
(30.01)
Submitted: 11/13/2009 12:05:26 PM :
Start Price:
$1.90
IDIX Score:
-129.38
IDIX has a too high valuation compared to its sales potential. It is also loss making.
Recs
Gumfactor
(38.38)
Submitted: 12/18/2008 1:12:17 PM :
Start Price:
$6.48
IDIX Score:
-102.22
Biotech = hot.
Recs
RNZ100
(88.54)
Submitted: 10/8/2008 8:28:03 PM :
Start Price:
$5.11
IDIX Score:
-64.82
Oversold (but then again, what isn't?!)
Recs
Biotech2008
(48.19)
Submitted: 1/4/2008 9:58:21 PM :
Start Price:
$2.72
IDIX Score:
+74.37
CSOakes @2.51
Recs
miralooku
(22.17)
Submitted: 7/16/2007 3:37:43 PM :
Start Price:
$3.63
IDIX Score:
+34.59
Oversold with powerful sponsor. Will rebound for at least a 50% gain.
Recs
ProphetOfProfits
(40.91)
Submitted: 7/13/2007 10:18:49 AM :
Start Price:
$3.88
IDIX Score:
+25.07
worth a buy for a short term correction below $4 after the crash
Recs
awolfson1015
(< 20)
Submitted: 6/26/2007 7:52:22 AM :
Start Price:
$6.72
IDIX Score:
-36.18
The company is sitting on a good amount of cash and has a major backer in the form of Novartis (NVS -- owns over 50% of IDIX's shares). Idenix currently sells a Hepatitis B drug and has a Hep C drug in Phase II trials. They are also working on an HIV drug that is in the extreme early phases of development. The Hep C drug will be used in combination with other drugs, but experienced a setback last year because of GI problems in some patients.
Honestly, I'm not a big biotech/pharma investor, but I like the idea behind this company's products and the potential for both the current Hep B drug and the possible Hep C drug. I generally avoid this realm because I don't have the background to understand the chemistry behind the drugs, but I figured this was an interesting situation to monitor through CAPS. Right now, the market is valuing this company as if it had very little chance at a future. NVS' support and the Hep B drug currently on market seem to mitigate against this pessimism.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 33 : 1 2 Next »